$41.81
3.86% today
Nasdaq, Apr 03, 06:49 pm CET
ISIN
US40131M1099
Symbol
GH

Guardant Health, Inc. Target price 2025 - Analyst rating & recommendation

Guardant Health, Inc. Classifications & Recommendation:

Buy
88%
Hold
8%
Sell
4%

Guardant Health, Inc. Price Target

Target Price $55.33
Price $43.49
Potential
Number of Estimates 21
21 Analysts have issued a price target Guardant Health, Inc. 2026 . The average Guardant Health, Inc. target price is $55.33. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 25 analysts: 22 Analysts recommend Guardant Health, Inc. to buy, 2 to hold and 1 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Guardant Health, Inc. stock has an average upside potential 2026 of . Most analysts recommend the Guardant Health, Inc. stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 739.02 856.43
31.04% 15.89%
EBITDA Margin -54.29% -26.63%
41.08% 50.95%
Net Margin -59.73% -41.73%
36.53% 30.13%

22 Analysts have issued a sales forecast Guardant Health, Inc. 2025 . The average Guardant Health, Inc. sales estimate is

$856m
Unlock
. This is
15.89% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$866m 17.17%
Unlock
, the lowest is
$842m 13.99%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $739m 31.04%
2025
$856m 15.89%
Unlock
2026
$1.0b 21.61%
Unlock
2027
$1.3b 22.66%
Unlock
2028
$1.5b 19.86%
Unlock
2029
$1.6b 5.60%
Unlock

16 Analysts have issued an Guardant Health, Inc. EBITDA forecast 2025. The average Guardant Health, Inc. EBITDA estimate is

$-228m
Unlock
. This is
43.14% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-135m 66.25%
Unlock
, the lowest is
$-284m 29.20%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $-401m 22.79%
2025
$-228m 43.15%
Unlock
2026
$-164m 27.90%
Unlock
2027
$-85.3m 48.15%
Unlock
2028
$-65.6m 23.06%
Unlock

EBITDA Margin

2024 -54.29% 41.08%
2025
-26.63% 50.95%
Unlock
2026
-15.79% 40.71%
Unlock
2027
-6.67% 57.76%
Unlock
2028
-4.28% 35.83%
Unlock

19 Guardant Health, Inc. Analysts have issued a net profit forecast 2025. The average Guardant Health, Inc. net profit estimate is

$-357m
Unlock
. This is
19.03% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-239m 45.79%
Unlock
, the lowest is
$-435m 1.41%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-441m 16.82%
2025
$-357m 19.03%
Unlock
2026
$-305m 14.74%
Unlock
2027
$-248m 18.72%
Unlock
2028
$-195m 21.32%
Unlock
2029
$-134m 31.39%
Unlock

Net Margin

2024 -59.73% 36.53%
2025
-41.73% 30.13%
Unlock
2026
-29.26% 29.88%
Unlock
2027
-19.39% 33.73%
Unlock
2028
-12.73% 34.35%
Unlock
2029
-8.27% 35.04%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -3.56 -2.88
16.82% 19.10%
P/E negative
EV/Sales 6.85

19 Analysts have issued a Guardant Health, Inc. forecast for earnings per share. The average Guardant Health, Inc. EPS is

$-2.88
Unlock
. This is
19.10% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-1.93 45.79%
Unlock
, the lowest is
$-3.51 1.40%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-3.56 16.82%
2025
$-2.88 19.10%
Unlock
2026
$-2.46 14.58%
Unlock
2027
$-2.00 18.70%
Unlock
2028
$-1.57 21.50%
Unlock
2029
$-1.08 31.21%
Unlock

P/E ratio

Current -12.23 153.73%
2025
-15.09 23.39%
Unlock
2026
-17.70 17.30%
Unlock
2027
-21.77 22.99%
Unlock
2028
-27.67 27.10%
Unlock
2029
-40.33 45.75%
Unlock

Based on analysts' sales estimates for 2025, the Guardant Health, Inc. stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 7.93 65.90%
2025
6.85 13.66%
Unlock
2026
5.63 17.77%
Unlock
2027
4.59 18.47%
Unlock
2028
3.83 16.57%
Unlock
2029
3.63 5.30%
Unlock

P/S ratio

Current 7.26 63.13%
2025
6.27 13.71%
Unlock
2026
5.15 17.77%
Unlock
2027
4.20 18.47%
Unlock
2028
3.51 16.57%
Unlock
2029
3.32 5.30%
Unlock

Current Guardant Health, Inc. Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
Stephens & Co.
Locked
Locked
Locked Mar 26 2025
Morgan Stanley
Locked
Locked
Locked Mar 06 2025
Piper Sandler
Locked
Locked
Locked Feb 26 2025
Scotiabank
Locked
Locked
Locked Feb 24 2025
Guggenheim
Locked
Locked
Locked Feb 24 2025
Canaccord Genuity
Locked
Locked
Locked Feb 24 2025
JP Morgan
Locked
Locked
Locked Feb 21 2025
Analyst Rating Date
Locked
Stephens & Co.:
Locked
Locked
Mar 26 2025
Locked
Morgan Stanley:
Locked
Locked
Mar 06 2025
Locked
Piper Sandler:
Locked
Locked
Feb 26 2025
Locked
Scotiabank:
Locked
Locked
Feb 24 2025
Locked
Guggenheim:
Locked
Locked
Feb 24 2025
Locked
Canaccord Genuity:
Locked
Locked
Feb 24 2025
Locked
JP Morgan:
Locked
Locked
Feb 21 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today